Profil
Sapan Shah is the founder and CEO of Glyscend, Inc. which was founded in 2023.
He previously held CEO positions at ARMGO Pharma, Inc., Shionogi, Inc., and StrideBio, Inc. Dr. Shah received an undergraduate degree from Northwestern University and a doctorate from Yale University.
Postes actifs de Sapan Shah
| Sociétés | Poste | Début |
|---|---|---|
Glyscend, Inc.
 Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD. | Fondateur | 05/09/2023 |
Anciens postes connus de Sapan Shah
| Sociétés | Poste | Fin |
|---|---|---|
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Directeur Général | - |
ARMGO Pharma, Inc.
 ARMGO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY. | Directeur Général | - |
StrideBio, Inc.
 StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Directeur Général | - |
Formation de Sapan Shah
| Yale University | Doctorate Degree |
| Northwestern University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Glyscend, Inc.
Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD. | Health Technology |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
ARMGO Pharma, Inc.
ARMGO Pharma, Inc. Pharmaceuticals: MajorHealth Technology ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY. | Health Technology |
